Hinge Health insider sells 15,000 shares under 10b5-1 plan

An officer of Hinge Health, Inc. reported selling 15,000 shares of the company’s Class A common stock on 12/22/2025.

Rhea-AI Filing Summary

An officer of Hinge Health, Inc. reported selling 15,000 shares of the company’s Class A common stock on 12/22/2025. The shares were sold in an open-market transaction at a weighted average price of $48.3967, with individual sale prices ranging from $47.785 to $48.74.

The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025, which is designed to allow insiders to trade on a scheduled basis. After this transaction, the reporting person beneficially owns 769,778 shares of Hinge Health’s Class A common stock. The total in Table I also reflects a correction to the reported ownership previously shown in Forms 4 filed on November 24, 2025 and December 1, 2025.

Insider Trade Summary

Net Seller: 15,000 shares

Net Sell 1 txn

Insider Pursley James

Role President

Sold 15,000 shs ($726K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	15,000	$48.3967	$726K

Holdings After Transaction: Class A Common Stock — 769,778 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $47.785 and the highest price at which shares were sold was $48.74. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Hinge Health (HNGE) report in this Form 4?

The filing reports that an officer of Hinge Health, Inc. sold 15,000 shares of the company’s Class A common stock on 12/22/2025.

At what price were the Hinge Health (HNGE) shares sold in this insider transaction?

The 15,000 shares were sold at a weighted average price of $48.3967, with individual sale prices ranging from $47.785 to $48.74.

Was the Hinge Health (HNGE) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025.

How many Hinge Health (HNGE) shares does the insider own after this transaction?

Following the reported sale, the reporting person beneficially owns 769,778 shares of Hinge Health’s Class A common stock.

Does this Hinge Health (HNGE) Form 4 include any corrections to prior filings?

Yes. The remarks state that the total number of shares shown in Column 5 of Table I reflects a correction to the ownership previously reported in Forms 4 filed on November 24, 2025 and December 1, 2025.

What is the reporting person’s role at Hinge Health (HNGE)?

The reporting person is identified as an officer of Hinge Health, Inc., serving in the role of President.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/23/2025 - 04:18 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pursley James

(Last) (First) (Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
12/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/22/2025		S(1)		15,000	D	$48.3967(2)	769,778	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $47.785 and the highest price at which shares were sold was $48.74. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Remarks:

This total number of shares set forth in Column 5 of Table I of this Form 4 reflects a correction to the number of shares of the Issuer's Class A Common owned by the Reporting Person as reported in Forms 4 filed on November 24, 2025 and December 1, 2025.

	/s/ James Budge, Attorney-in-Fact	12/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.